TauroLock - Model HEP100 - Catheter Lock Solution

TauroLock™-HEP100 has been approved for instillation in all central-venous access systems. This lock solution prevents the formation of a bacterial biofilm and thereby protects patients from catheter-related infections. At the same time, it ensures a high patency rate. We recommend TauroLock™-HEP100 for CVCs in oncology and parenteral nutrition.

TauroLock™-HEP100 contains three active ingredients:

• taurolidine
• heparin (100 units per ml)
• citrate (4 %)

Taurolidine has a broad antimicrobial activity (incl. MRSA and VRE) against gram-positive and gram-negative bacteria and fungi (e.g. Candida). Heparin and citrate both help to prevent occlusions within the catheter.

In-between treatment sessions, TauroLock™-HEP100 is instilled into the saline-flushed access system. Please note that medical staff must check the filling volume of the respective catheter or port system.

Patients diagnosed with HIT should not use TauroLock™-HEP100 for their vascular access system (VAD). Instead, we recommend TauroLock™ and/ or TauroLock™-U25.000. Furthermore, TauroLock™ is not suitable if:

• patients have displayed a hypersensitive reaction to citrate or taurolidine
• patients are taking medication which interferes with either citrate, heparin, or taurolidine.